Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

New hypoglycaemic launched

Sitagliptin (Januvia®), the first in a new class of hypoglycaemics has been launched. The Summary of Product Characteristics is available on the Electronic Medicine Compendium.

Sitagliptin is licensed for adjunctive use with metformin or a glitazone in patients with type 2 diabetes to improve glycaemic control. It is available as a 100mg tablet with dosing as a single daily administration. It is the first in a new class of agents called dipeptidyl peptidase 4 (DPP-4) inhibitors which enhance the levels of the incretin hormones naturally secreted after eating food. These hormones act physiologically to increase insulin secretion and decrease glucagon secretion.

As this is a new drug data are limited, however based on research experience:

  • It is not recommended for use in anyone under 18 years old due to insufficient safety and efficacy data
  • Care should be used in patients aged over 75 years old as only limited data are available. No dose adjustment is expected to be necessary
  • No dose adjustment is required in mild renal insufficiency (creatinine clearance greater than 50ml/min). Sitagliptin should not be used in patients with moderate to severe renal insufficiency
  • No dose adjustment is required for mild to moderate hepatic insufficiency. No data are available in severe hepatic insufficiency, use is not recommended
  • No data are available in pregnancy or breast feeding, use is not recommended

In clinical studies in 2,700 patients of up to 2 years in duration the most commonly observed side effects included nausea, upper abdominal pain, diarrhoea, somnolence, anorexia, weight loss and hypoglycaemia.

As with all new drugs, initial use should be cautious. This drug is a useful addition to the currently available hypoglycaemics. It may be useful in patients already on metformin who are contraindicated to or suffer intolerable side effects from sulphonylureas or glitazones.

Action: Clinicians should be aware of this new class of drugs. An initially cautious approach to use would place them as last line agents when contraindications or side effects are limiting use of existing therapies.

Share 'New hypoglycaemic launched' on Email Share 'New hypoglycaemic launched' on Delicious Share 'New hypoglycaemic launched' on Digg Share 'New hypoglycaemic launched' on Facebook Share 'New hypoglycaemic launched' on Google+ Share 'New hypoglycaemic launched' on reddit Share 'New hypoglycaemic launched' on StumbleUpon Share 'New hypoglycaemic launched' on Twitter

atomic-wealth

One Comments to “New hypoglycaemic launched”

  1. [...] (Galvus®), the second in a new class of hypoglycaemics has been [...]

    Pingback by Prescribing Advice for GPs » Second gliptin launched — March 25, 2008 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 788,914 spam comments.

atomic-wealth
fond-illness
summer